Prospective study of palliative hypofractionated radiotherapy (8.5 Gy x 2) for patients with symptomatic non-small-cell lung cancer

被引:30
作者
Cross, CK
Berman, S
Buswell, L
Johnson, B
Baldini, EH
机构
[1] Harvard Univ, Brigham & Womens Hosp, Sch Med,Dana Farber Canc Inst, Joint Ctr Radiat Therapy,Dept Radiat Oncol, Boston, MA 02115 USA
[2] Harvard Univ, Brigham & Womens Hosp, Sch Med,Dana Farber Canc Inst, Lowe Ctr Thorac Oncol,Dept Adult Oncol, Boston, MA 02115 USA
[3] Beth Israel Deaconess Med Ctr, Dept Radiat Oncol, Boston, MA 02115 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2004年 / 58卷 / 04期
关键词
hypofractionation; palliation; lung cancer;
D O I
10.1016/j.ijrobp.2003.08.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Hypofractionated chest radiotherapy regimens have provided excellent palliation of pulmonary symptoms in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status in studies from Asia and Europe. We conducted a prospective study of this approach in patients from the United States. Methods and Materials: Twenty-three patients with symptomatic NSCLC and an Eastern Cooperative Oncology Group performance status of greater than or equal to2 were enrolled between December 1994 and October 2001. Two "involved-field" fractions of 8.5 Gy were delivered 1 week apart. Patients were assessed for efficacy, toxicity, and tumor response at baseline, treatment completion, and 1 week, 1 month, and 4 months after completing radiotherapy. Results: The median follow-up after treatment began was 4.3 months (range, 0.3-38). The median forced expiratory volume in 1 s and Eastern Cooperative Oncology Group performance status as measured at baseline was 1.05 L and 3, respectively. The most common presenting pulmonary symptoms were dyspnea (100%), cough (96%), anorexia/nausea (65%), and chest pain (52%). Between treatment completion and up to 4 months after treatment, dyspnea, cough, anorexia/nausea, chest pain, hoarseness, hemoptysis, and dysphagia had improved in 30%, 60%, 67%, 75%, 25%, 100%, and 100% of patients, respectively. No cases of treatment-related esophagitis, pneumonitis, or radiation myelopathy occurred. Progressive local disease was seen in only 1 (6%) of 18 assessable patients 4 months after treatment. Conclusion: For patients with poor performance status and inoperable NSCLC causing pulmonary symptoms, hypofractionated, involved-field radiotherapy, 8.5 Gy in two fractions, offers acceptable palliation with minimal toxicity. A clear advantage of the very short hypofractionated regimen is that it enables patients with a short expected survival time to spend more of their remaining time away from the hospital. (C) 2004 Elsevier Inc.
引用
收藏
页码:1098 / 1105
页数:8
相关论文
共 28 条
[1]  
[Anonymous], CANC FACTS FIG 2003
[2]  
Appold S, 1999, STRAHLENTHER ONKOL, V175, P267, DOI 10.1007/BF02743577
[3]  
ARBUCK SG, 1998, COMMON TOXICITY CRIT
[4]   Palliative radiation therapy for non-small cell lung cancer [J].
Baldini, EH .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1997, 11 (02) :303-&
[5]   A MEDICAL-RESEARCH COUNCIL (MRC) RANDOMIZED TRIAL OF PALLIATIVE RADIOTHERAPY WITH 2 FRACTIONS OR A SINGLE FRACTION IN PATIENTS WITH INOPERABLE NON-SMALL-CELL LUNG-CANCER (NSCLC) AND POOR PERFORMANCE STATUS [J].
BLEEHEN, NM ;
BOLGER, JJ ;
GIRLING, DJ ;
HASLETON, PS ;
HOPWOOD, P ;
MACBETH, FR ;
MACHIN, D ;
MOGHISSI, K ;
SAUNDERS, M ;
STEPHENS, RJ ;
THATCHER, N ;
WHITE, RJ .
BRITISH JOURNAL OF CANCER, 1992, 65 (06) :934-941
[6]   Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: Sobering results [J].
Breathnach, OS ;
Freidlin, B ;
Conley, B ;
Green, MR ;
Johnson, DH ;
Gandara, DR ;
O'Connell, M ;
Shepherd, FA ;
Johnson, BE .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) :1734-1742
[7]  
COLLINS TM, 1988, CLIN RADIOL, V39, P284, DOI 10.1016/S0009-9260(88)80398-2
[8]   TOXICITY CRITERIA OF THE RADIATION-THERAPY ONCOLOGY GROUP (RTOG) AND THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER (EORTC) [J].
COX, JD ;
STETZ, J ;
PAJAK, TF .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (05) :1341-1346
[9]   CELLULAR RECOVERY IN HUMAN SKIN REACTIONS - APPLICATION TO DOSE FRACTION NUMBER OVERALL TIME RELATIONSHIP IN RADIOTHERAPY [J].
DUTREIX, J ;
WAMBERSIE, A ;
BOUNIK, C .
EUROPEAN JOURNAL OF CANCER, 1973, 9 (03) :159-167
[10]  
ENAMI B, 1991, INT J RADIAT ONCOL, V21, P109